Lyme Disease

View All

Pharma News for Merck, Roche, AbbVie, Abbisko Pfizer
FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus Padcev; Roche and Carmot Therapeutics’s Definitive Merger Agreement; AbbVie to Acquire ImmunoGen; FDA Grants Orphan Drug Designation to LP-284; Merck Announces Commercialization Agreement With Abbisko; Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial

FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus Padcev for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Merck, operating as MSD internationally, reported that the U.S. Food and Drug Administration (FDA) has prioritized the review of a supplementar...

Find More

Lyme Disease
Beware! Season of Lyme has come

The summer has arrived, and so has the season of Lyme. The number of Lyme disease cases invariably rises as the months of June and July approach. According to the CDC, the number of Lyme diseases diagnosed cases each year is 30,000. And this number is likely to cross 40,000 each year in the United States. The Lyme ...

Find More